ABAXIS (ABAX) Receives Media Sentiment Rating of 0.05
Headlines about ABAXIS (NASDAQ:ABAX) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ABAXIS earned a news impact score of 0.05 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 46.4499415928081 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
ABAXIS (ABAX) opened at 46.65 on Friday. ABAXIS has a 52-week low of $44.12 and a 52-week high of $55.95. The firm has a market cap of $1.05 billion, a PE ratio of 32.94 and a beta of 0.81. The company’s 50 day moving average price is $50.43 and its 200 day moving average price is $49.39.
ABAXIS (NASDAQ:ABAX) last posted its quarterly earnings results on Thursday, July 27th. The medical research company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by $0.05. ABAXIS had a return on equity of 10.85% and a net margin of 14.12%. The business had revenue of $58.26 million for the quarter, compared to the consensus estimate of $60.37 million. During the same quarter in the previous year, the business posted $0.30 EPS. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. Analysts predict that ABAXIS will post $1.13 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, September 1st will be issued a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date of this dividend is Wednesday, August 30th. ABAXIS’s payout ratio is currently 39.72%.
Several analysts have recently issued reports on the company. Zacks Investment Research downgraded ABAXIS from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. BidaskClub downgraded ABAXIS from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 3rd. Stifel Nicolaus reiterated a “hold” rating and set a $48.00 price target on shares of ABAXIS in a research note on Friday, July 14th. Finally, Aegis assumed coverage on ABAXIS in a research note on Friday, June 9th. They set a “hold” rating and a $56.50 price target for the company. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. ABAXIS currently has a consensus rating of “Hold” and a consensus target price of $47.88.
In other ABAXIS news, insider Achim Henkel sold 650 shares of the firm’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $48.87, for a total transaction of $31,765.50. Following the completion of the sale, the insider now directly owns 58,950 shares in the company, valued at $2,880,886.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.10% of the company’s stock.
ABAXIS Company Profile
Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.
Receive News & Ratings for ABAXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABAXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.